{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:24:41Z","timestamp":1792027481537,"version":"4.4.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82301211"],"award-info":[{"award-number":["82301211"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Beijing Natural Science Foundation","award":["J230028"],"award-info":[{"award-number":["J230028"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"DOI":"10.1007\/s10792-025-03836-4","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T08:45:48Z","timestamp":1762332348000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Real-life short-term experience of switching from other anti-VEGF therapy to faricimab in patients with refractory macular edema secondary to retinal vein occlusion in China"],"prefix":"10.1007","volume":"45","author":[{"given":"Yaoyao","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingwei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijun","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,5]]},"reference":[{"issue":"2","key":"3836_CR1","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.ophtha.2009.07.017","volume":"117","author":"S Rogers","year":"2010","unstructured":"Rogers S, McIntosh RL, Cheung N, Lim L, Wang JJ, Mitchell P, Kowalski JW, Nguyen H, Wong TY, International Eye Disease C (2010) The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 117(2):313\u2013319. https:\/\/doi.org\/10.1016\/j.ophtha.2009.07.017","journal-title":"Ophthalmology"},{"issue":"1","key":"3836_CR2","doi-asserted-by":"publisher","first-page":"40","DOI":"10.22608\/APO.2017442","volume":"7","author":"M Ip","year":"2018","unstructured":"Ip M, Hendrick A (2018) Retinal vein occlusion review. Asia Pac J Ophthalmol (Phila) 7(1):40\u201345. https:\/\/doi.org\/10.22608\/APO.2017442","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"issue":"1","key":"3836_CR3","doi-asserted-by":"publisher","first-page":"010427","DOI":"10.7189\/jogh.09.010427","volume":"9","author":"P Song","year":"2019","unstructured":"Song P, Xu Y, Zha M, Zhang Y, Rudan I (2019) Global epidemiology of retinal vein occlusion: a systematic review and meta-analysis of prevalence, incidence, and risk factors. J Glob Health 9(1):010427. https:\/\/doi.org\/10.7189\/jogh.09.010427","journal-title":"J Glob Health"},{"issue":"3","key":"3836_CR4","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1080\/08998280.2023.2173938","volume":"36","author":"P Kalva","year":"2023","unstructured":"Kalva P, Akram R, Zuberi HZ, Kooner KS (2023) Prevalence and risk factors of retinal vein occlusion in the United States: the national health and nutrition examination survey, 2005 to 2008. Proc (Bayl Univ Med Cent) 36(3):335\u2013340. https:\/\/doi.org\/10.1080\/08998280.2023.2173938","journal-title":"Proc (Bayl Univ Med Cent)"},{"issue":"2","key":"3836_CR5","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s00417-020-04932-0","volume":"259","author":"JV Costa","year":"2021","unstructured":"Costa JV, Moura-Coelho N, Abreu AC, Neves P, Ornelas M, Furtado MJ (2021) Macular edema secondary to retinal vein occlusion in a real-life setting: a multicenter, nationwide, 3-year follow-up study. Graefes Arch Clin Exp Ophthalmol 259(2):343\u2013350. https:\/\/doi.org\/10.1007\/s00417-020-04932-0","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"3836_CR6","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1186\/s12967-024-05441-y","volume":"22","author":"L Sha","year":"2024","unstructured":"Sha L, Zhao Y, Li S, Wei D, Tao Y, Wang Y (2024) Insights to Ang\/Tie signaling pathway: another rosy dawn for treating retinal and choroidal vascular diseases. J Transl Med 22(1):898. https:\/\/doi.org\/10.1186\/s12967-024-05441-y","journal-title":"J Transl Med"},{"key":"3836_CR7","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.preteyeres.2017.10.006","volume":"63","author":"A Daruich","year":"2018","unstructured":"Daruich A, Matet A, Moulin A, Kowalczuk L, Nicolas M, Sellam A, Rothschild PR, Omri S, Gelize E, Jonet L, Delaunay K, De Kozak Y, Berdugo M, Zhao M, Crisanti P, Behar-Cohen F (2018) Mechanisms of macular edema: beyond the surface. Prog Retin Eye Res 63:20\u201368. https:\/\/doi.org\/10.1016\/j.preteyeres.2017.10.006","journal-title":"Prog Retin Eye Res"},{"issue":"7","key":"3836_CR8","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1016\/j.ophtha.2015.04.006","volume":"122","author":"PA Campochiaro","year":"2015","unstructured":"Campochiaro PA, Hafiz G, Mir TA, Scott AW, Solomon S, Zimmer-Galler I, Sodhi A, Duh E, Ying H, Wenick A, Shah SM, Do DV, Nguyen QD, Kherani S, Sophie R (2015) Scatter photocoagulation does not reduce macular edema or treatment burden in patients with retinal vein occlusion: the RELATE trial. Ophthalmology 122(7):1426\u20131437. https:\/\/doi.org\/10.1016\/j.ophtha.2015.04.006","journal-title":"Ophthalmology"},{"issue":"6","key":"3836_CR9","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/j.ophtha.2010.03.032","volume":"117","author":"JA Haller","year":"2010","unstructured":"Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jacques ML, Jiao J, Li XY, Whitcup SM, OGS Group (2010) Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 117(6):1134\u20131146. https:\/\/doi.org\/10.1016\/j.ophtha.2010.03.032","journal-title":"Ophthalmology"},{"issue":"5","key":"3836_CR10","doi-asserted-by":"publisher","first-page":"876","DOI":"10.18240\/ijo.2025.05.13","volume":"18","author":"G Karata\u015f","year":"2025","unstructured":"Karata\u015f G, \u00c7ak\u0131r A, Uzundede T, Aday \u00d6, \u00d6zo\u011fuz AM, Karata\u015f ME, Kabakc\u0131 AK (2025) Dexamethasone intravitreal implant monotherapy in naive patients with macular edema secondary to retinal vein occlusion: long term follow-up retrospective cohort study. Int J Ophthalmol 18(5):876\u2013882. https:\/\/doi.org\/10.18240\/ijo.2025.05.13","journal-title":"Int J Ophthalmol"},{"issue":"5","key":"3836_CR11","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/s41433-022-02007-4","volume":"36","author":"L Nicholson","year":"2022","unstructured":"Nicholson L, Talks SJ, Amoaku W, Talks K, Sivaprasad S (2022) Retinal vein occlusion (RVO) guideline: executive summary. Eye (Lond) 36(5):909\u2013912. https:\/\/doi.org\/10.1038\/s41433-022-02007-4","journal-title":"Eye (Lond)"},{"issue":"5","key":"3836_CR12","doi-asserted-by":"publisher","first-page":"860","DOI":"10.18240\/ijo.2025.05.11","volume":"18","author":"YY Sun","year":"2025","unstructured":"Sun YY, Meng J, Li SS, Xiao Q, Zhang TZ, Miao H, Zhao MW, Qi HJ (2025) Effect of simultaneous intravitreal ranibizumab and extended-release dexamethasone injection on patients with na\u00efve versus refractory retinal vein occlusion macular edema: a prospective, multicenter, and interventional open-label study. Int J Ophthalmol 18(5):860\u2013867. https:\/\/doi.org\/10.18240\/ijo.2025.05.11","journal-title":"Int J Ophthalmol"},{"issue":"3","key":"3836_CR13","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.bbrc.2014.08.096","volume":"452","author":"R Zhao","year":"2014","unstructured":"Zhao R, Qian L, Jiang L (2014) Mirna-dependent cross-talk between VEGF and Ang-2 in hypoxia-induced microvascular dysfunction. Biochem Biophys Res Commun 452(3):428\u2013435. https:\/\/doi.org\/10.1016\/j.bbrc.2014.08.096","journal-title":"Biochem Biophys Res Commun"},{"issue":"Suppl 2","key":"3836_CR14","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41433-024-02936-2","volume":"38","author":"A Chang","year":"2024","unstructured":"Chang A, Kotecha A, Kermani F, Saffar I (2024) Infographic: study design of the BALATON and COMINO phase 3 randomised trials of faricimab in patients with retinal vein occlusion. Eye (Lond) 38(Suppl 2):55\u201356. https:\/\/doi.org\/10.1038\/s41433-024-02936-2","journal-title":"Eye (Lond)"},{"issue":"3","key":"3836_CR15","doi-asserted-by":"publisher","first-page":"100302","DOI":"10.1016\/j.xops.2023.100302","volume":"3","author":"LO Hattenbach","year":"2023","unstructured":"Hattenbach LO, Abreu F, Arrisi P, Basu K, Danzig CJ, Guymer R, Haskova Z, Heier JS, Kotecha A, Liu Y, Loewenstein A, Seres A, Willis JR, Wykoff CC, Paris LP (2023) Balaton and Comino: phase III randomized clinical trials of faricimab for retinal vein occlusion: study design and rationale. Ophthalmol Sci 3(3):100302. https:\/\/doi.org\/10.1016\/j.xops.2023.100302","journal-title":"Ophthalmol Sci"},{"issue":"8","key":"3836_CR16","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.ophtha.2024.01.029","volume":"131","author":"R Tadayoni","year":"2024","unstructured":"Tadayoni R, Paris LP, Danzig CJ, Abreu F, Khanani AM, Brittain C, Lai TYY, Haskova Z, Sakamoto T, Kotecha A, Schlottmann PG, Liu Y, Seres A, Retiere AC, Willis JR, Yoon YH, Balaton, Investigators C (2024) Efficacy and safety of faricimab for macular edema due to retinal vein occlusion: 24-week results from the BALATON and COMINO trials. Ophthalmology 131(8):950\u2013960. https:\/\/doi.org\/10.1016\/j.ophtha.2024.01.029","journal-title":"Ophthalmology"},{"issue":"5","key":"3836_CR17","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.survophthal.2019.02.008","volume":"64","author":"J Talks","year":"2019","unstructured":"Talks J, Daien V, Finger RP, Eldem B, Sakamoto T, Cardillo JA, Mitchell P, Wong TY, Korobelnik JF (2019) The use of real-world evidence for evaluating anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration. Surv Ophthalmol 64(5):707\u2013719. https:\/\/doi.org\/10.1016\/j.survophthal.2019.02.008","journal-title":"Surv Ophthalmol"},{"issue":"10","key":"3836_CR18","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.18240\/ijo.2024.10.09","volume":"17","author":"YY Zhong","year":"2024","unstructured":"Zhong YY, Tang C, Zhang LY, Zhang XD, Liu SL (2024) Dexamethasone implant for refractory macular edema secondary to diabetic retinopathy and retinal vein occlusion. Int J Ophthalmol 17(10):1837\u20131842. https:\/\/doi.org\/10.18240\/ijo.2024.10.09","journal-title":"Int J Ophthalmol"},{"issue":"7","key":"3836_CR19","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1097\/IAE.0b013e3181d87e04","volume":"30","author":"NZ Gregori","year":"2010","unstructured":"Gregori NZ, Feuer W, Rosenfeld PJ (2010) Novel method for analyzing snellen visual acuity measurements. Retina 30(7):1046\u20131050. https:\/\/doi.org\/10.1097\/IAE.0b013e3181d87e04","journal-title":"Retina"},{"issue":"7","key":"3836_CR20","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1007\/s00417-024-06421-0","volume":"262","author":"M Schneider","year":"2024","unstructured":"Schneider M, Bjerager J, Hodzic-Hadzibegovic D, Klefter ON, Subhi Y, Hajari J (2024) Short-term outcomes of treatment switch to faricimab in patients with aflibercept-resistant neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 262(7):2153\u20132162. https:\/\/doi.org\/10.1007\/s00417-024-06421-0","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"9","key":"3836_CR21","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.oret.2022.02.007","volume":"6","author":"MR Munk","year":"2022","unstructured":"Munk MR, Kashani AH, Tadayoni R, Korobelnik JF, Wolf S, Pichi F, Koh A, Ishibazawa A, Gaudric A, Loewenstein A, Lumbroso B, Ferrara D, Sarraf D, Wong DT, Skondra D, Rodriguez FJ, Staurenghi G, Pearce I, Kim JE, Freund KB, Parodi MB, Waheed NK, Rosen R, Spaide RF, Nakao S, Sadda S, Vujosevic S, Wong TY, Murata T, Chakravarthy U, Ogura Y, Huf W, Tian M (2022) Recommendations for OCT angiography reporting in retinal vascular disease: a Delphi approach by international experts. Ophthalmol Retina 6(9):753\u2013761. https:\/\/doi.org\/10.1016\/j.oret.2022.02.007","journal-title":"Ophthalmol Retina"},{"issue":"1","key":"3836_CR22","doi-asserted-by":"publisher","first-page":"P182","DOI":"10.1016\/j.ophtha.2015.10.045","volume":"123","author":"JS Pulido","year":"2016","unstructured":"Pulido JS, Flaxel CJ, Adelman RA, Hyman L, Folk JC, Olsen TW (2016) Retinal vein occlusions preferred practice pattern((R)) guidelines. Ophthalmology 123(1):P182-208. https:\/\/doi.org\/10.1016\/j.ophtha.2015.10.045","journal-title":"Ophthalmology"},{"issue":"6","key":"3836_CR23","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1097\/IAE.0b013e3181a2c1c3","volume":"29","author":"F Forooghian","year":"2009","unstructured":"Forooghian F, Cukras C, Meyerle CB, Chew EY, Wong WT (2009) Tachyphylaxis after intravitreal bevacizumab for exudative age-related macular degeneration. Retina 29(6):723\u2013731. https:\/\/doi.org\/10.1097\/IAE.0b013e3181a2c1c3","journal-title":"Retina"},{"issue":"7","key":"3836_CR24","doi-asserted-by":"publisher","first-page":"3115","DOI":"10.1167\/iovs.08-1689","volume":"49","author":"PA Keane","year":"2008","unstructured":"Keane PA, Liakopoulos S, Ongchin SC, Heussen FM, Msutta S, Chang KT, Walsh AC, Sadda SR (2008) Quantitative subanalysis of optical coherence tomography after treatment with ranibizumab for neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 49(7):3115\u20133120. https:\/\/doi.org\/10.1167\/iovs.08-1689","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"12","key":"3836_CR25","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1016\/j.ophtha.2008.07.007","volume":"115","author":"S Schaal","year":"2008","unstructured":"Schaal S, Kaplan HJ, Tezel TH (2008) Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration? Ophthalmology 115(12):2199\u20132205. https:\/\/doi.org\/10.1016\/j.ophtha.2008.07.007","journal-title":"Ophthalmology"},{"key":"3836_CR26","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.2147\/OPTH.S116539","volume":"10","author":"J Hall","year":"2016","unstructured":"Hall J (2016) Impact of injection therapy on retinal patients with diabetic macular edema or retinal vein occlusion. Clin Ophthalmol 10:1631\u20131632. https:\/\/doi.org\/10.2147\/OPTH.S116539","journal-title":"Clin Ophthalmol"},{"issue":"10326","key":"3836_CR27","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, Figueroa MS, Lin H, Holz FG, Patel V, Lai TYY, Silverman D, Regillo C, Swaminathan B, Viola F, Cheung CMG, Wong TY, Tenaya, Investigators L (2022) Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet 399(10326):729\u2013740. https:\/\/doi.org\/10.1016\/S0140-6736(22)00010-1","journal-title":"Lancet"},{"issue":"1","key":"3836_CR28","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s40123-023-00830-w","volume":"13","author":"A Giocanti-Auregan","year":"2024","unstructured":"Giocanti-Auregan A, Donati S, Hoerauf H, Allmeier H, Rittenhouse KD, Machewitz T, Yang CH, Investigators AS (2024) Real-world management of macular edema secondary to retinal vein occlusion with intravitreal aflibercept: 24-month results from the AURIGA observational study. Ophthalmol Ther 13(1):179\u2013203. https:\/\/doi.org\/10.1007\/s40123-023-00830-w","journal-title":"Ophthalmol Ther"},{"key":"3836_CR29","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s40942-020-00250-z","volume":"6","author":"QD Nguyen","year":"2020","unstructured":"Nguyen QD, Heier JS, Do DV, Mirando AC, Pandey NB, Sheng H, Heah T (2020) The Tie2 signaling pathway in retinal vascular diseases: a novel therapeutic target in the eye. Int J Retina Vitreous 6:48. https:\/\/doi.org\/10.1186\/s40942-020-00250-z","journal-title":"Int J Retina Vitreous"},{"issue":"5","key":"3836_CR30","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1007\/s40123-023-00753-6","volume":"12","author":"HO Larsen","year":"2023","unstructured":"Larsen HO, Grauslund J, Vergmann AS (2023) Efficacy, durability and safety of faricimab in neovascular age-related macular degeneration and diabetic macular oedema: lessons learned from registration trials. Ophthalmol Ther 12(5):2253\u20132264. https:\/\/doi.org\/10.1007\/s40123-023-00753-6","journal-title":"Ophthalmol Ther"},{"issue":"11\u201312","key":"3836_CR31","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1007\/s13300-022-01326-9","volume":"13","author":"JD Collazos-Aleman","year":"2022","unstructured":"Collazos-Aleman JD, Gnecco-Gonzalez S, Jaramillo-Zarama B, Jimenez-Mora MA, Mendivil CO (2022) The role of angiopoietins in neovascular diabetes-related retinal diseases. Diabetes Ther 13(11\u201312):1811\u20131821. https:\/\/doi.org\/10.1007\/s13300-022-01326-9","journal-title":"Diabetes Ther"},{"key":"3836_CR32","doi-asserted-by":"publisher","first-page":"176691","DOI":"10.1016\/j.ejphar.2024.176691","volume":"976","author":"A Kuriyama","year":"2024","unstructured":"Kuriyama A, Nakamura S, Inokuchi Y, Abe H, Yasuda H, Hidaka Y, Nagaoka K, Soeda T, Shimazawa M, Hara H (2024) The protective effect of anti-VEGF-A\/Ang-2 bispecific antibody on retinal vein occlusion model mice. Eur J Pharmacol 976:176691. https:\/\/doi.org\/10.1016\/j.ejphar.2024.176691","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"3836_CR33","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1167\/iovs.16-20575","volume":"58","author":"L Ma","year":"2017","unstructured":"Ma L, Brelen ME, Tsujikawa M, Chen H, Chu WK, Lai TY, Ng DS, Sayanagi K, Hara C, Hashida N, Chan VC, Tam PO, Young AL, Chen W, Nishida K, Pang CP, Chen LJ (2017) Identification of ANGPT2 as a new gene for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy in the Chinese and Japanese populations. Invest Ophthalmol Vis Sci 58(2):1076\u20131083. https:\/\/doi.org\/10.1167\/iovs.16-20575","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"11","key":"3836_CR34","doi-asserted-by":"publisher","first-page":"3125","DOI":"10.1007\/s00417-023-06071-8","volume":"261","author":"K Takahashi","year":"2023","unstructured":"Takahashi K, Cheung CMG, Iida T, Lai TYY, Ohji M, Yanagi Y, Kawano M, Ohsawa S, Suzuki T, Kotecha A, Lin H, Patel V, Swaminathan B, Lee WK, Tenaya LI (2023) Efficacy, durability, and safety of faricimab in patients from Asian countries with neovascular age-related macular degeneration: 1-year subgroup analysis of the TENAYA and LUCERNE trials. Graefes Arch Clin Exp Ophthalmol 261(11):3125\u20133137. https:\/\/doi.org\/10.1007\/s00417-023-06071-8","journal-title":"Graefes Arch Clin Exp Ophthalmol"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-025-03836-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-025-03836-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-025-03836-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T19:01:45Z","timestamp":1766170905000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-025-03836-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,5]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3836"],"URL":"https:\/\/doi.org\/10.1007\/s10792-025-03836-4","relation":{},"ISSN":["1573-2630"],"issn-type":[{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,5]]},"assertion":[{"value":"14 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This retrospective study was granted approval by the Medical Ethics Committee of Peking University People\u2019s Hospital. All procedures conducted during the study strictly adhered to the principles outlined in the Declaration of Helsinki. Due to the minimal or negligible risk posed to participants, the review board determined that the acquisition of written informed consent was not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"463"}}